Nifty
Sensex
:
:
22147.00
73088.33
151.15 (0.69%)
599.34 (0.83%)

Pharmaceuticals & Drugs - Global

Rating :
71/99

BSE: 524742 | NSE: CAPLIPOINT

1311.70
19-Apr-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1318.00
  •  1318.00
  •  1290.00
  •  1316.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  72593
  •  949.43
  •  1619.05
  •  646.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 9,986.72
  • 22.82
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 9,422.71
  • 0.34%
  • 4.55

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 70.62%
  • 1.41%
  • 17.59%
  • FII
  • DII
  • Others
  • 3.32%
  • 1.07%
  • 5.99%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 17.72
  • 11.39

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 13.70
  • 6.32

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 16.34
  • 15.81

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.87
  • 17.76
  • 19.48

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.48
  • 3.96
  • 4.07

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.77
  • 12.06
  • 13.34

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
435.50
372.07
17.05%
410.06
359.05
14.21%
395.32
346.33
14.15%
389.28
339.24
14.75%
Expenses
293.22
262.70
11.62%
272.66
253.47
7.57%
268.79
244.15
10.09%
265.35
239.30
10.89%
EBITDA
142.28
109.37
30.09%
137.40
105.58
30.14%
126.53
102.18
23.83%
123.93
99.94
24.00%
EBIDTM
32.67%
29.39%
33.51%
29.41%
32.01%
29.50%
31.84%
29.46%
Other Income
17.18
14.15
21.41%
20.43
16.48
23.97%
12.04
13.94
-13.63%
11.40
11.51
-0.96%
Interest
0.17
0.36
-52.78%
0.18
0.14
28.57%
0.28
0.06
366.67%
0.23
0.08
187.50%
Depreciation
13.90
11.43
21.61%
11.76
11.46
2.62%
11.38
10.97
3.74%
11.13
11.45
-2.79%
PBT
145.39
111.73
30.13%
145.89
110.46
32.07%
126.91
105.09
20.76%
123.97
99.92
24.07%
Tax
25.59
14.35
78.33%
29.86
18.42
62.11%
22.76
18.78
21.19%
22.81
19.09
19.49%
PAT
119.80
97.38
23.02%
116.03
92.04
26.06%
104.15
86.31
20.67%
101.16
80.83
25.15%
PATM
27.51%
26.17%
28.30%
25.63%
26.35%
24.92%
25.99%
23.83%
EPS
15.43
12.84
20.17%
15.12
12.09
25.06%
13.62
11.21
21.50%
13.45
10.43
28.95%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Net Sales
1,630.16
1,466.73
1,269.41
1,061.29
863.20
648.69
539.84
401.65
238.72
251.77
173.09
Net Sales Growth
15.07%
15.54%
19.61%
22.95%
33.07%
20.16%
34.41%
68.25%
-5.18%
45.46%
 
Cost Of Goods Sold
709.41
663.21
557.51
471.74
413.16
288.78
238.18
184.93
121.16
135.62
102.58
Gross Profit
920.75
803.52
711.90
589.55
450.04
359.91
301.66
216.72
117.56
116.15
70.50
GP Margin
56.48%
54.78%
56.08%
55.55%
52.14%
55.48%
55.88%
53.96%
49.25%
46.13%
40.73%
Total Expenditure
1,100.02
1,026.21
874.88
737.04
603.13
416.84
344.52
276.84
174.51
192.06
136.90
Power & Fuel Cost
-
25.53
21.40
16.36
14.81
13.76
10.98
9.91
7.56
8.61
3.07
% Of Sales
-
1.74%
1.69%
1.54%
1.72%
2.12%
2.03%
2.47%
3.17%
3.42%
1.77%
Employee Cost
-
136.12
114.74
101.97
67.15
45.58
37.61
29.71
17.92
18.24
12.63
% Of Sales
-
9.28%
9.04%
9.61%
7.78%
7.03%
6.97%
7.40%
7.51%
7.24%
7.30%
Manufacturing Exp.
-
90.99
82.01
69.85
68.23
43.49
37.11
28.56
14.33
16.04
7.42
% Of Sales
-
6.20%
6.46%
6.58%
7.90%
6.70%
6.87%
7.11%
6.00%
6.37%
4.29%
General & Admin Exp.
-
85.38
66.68
38.53
25.50
20.82
12.27
13.78
8.15
7.97
6.54
% Of Sales
-
5.82%
5.25%
3.63%
2.95%
3.21%
2.27%
3.43%
3.41%
3.17%
3.78%
Selling & Distn. Exp.
-
18.78
27.52
18.03
9.95
2.08
5.92
9.41
2.29
2.85
1.46
% Of Sales
-
1.28%
2.17%
1.70%
1.15%
0.32%
1.10%
2.34%
0.96%
1.13%
0.84%
Miscellaneous Exp.
-
6.20
5.02
20.56
4.33
2.33
2.45
0.55
3.10
2.72
1.46
% Of Sales
-
0.42%
0.40%
1.94%
0.50%
0.36%
0.45%
0.14%
1.30%
1.08%
1.84%
EBITDA
530.14
440.52
394.53
324.25
260.07
231.85
195.32
124.81
64.21
59.71
36.19
EBITDA Margin
32.52%
30.03%
31.08%
30.55%
30.13%
35.74%
36.18%
31.07%
26.90%
23.72%
20.91%
Other Income
61.05
56.52
38.89
27.93
41.33
19.03
12.67
9.96
3.66
3.03
3.72
Interest
0.86
0.78
0.70
1.59
0.32
0.58
0.61
0.52
0.34
0.97
0.68
Depreciation
48.17
44.99
46.90
36.97
31.62
23.43
19.00
13.30
7.48
8.38
3.54
PBT
542.16
451.27
385.82
313.62
269.46
226.88
188.38
120.95
60.05
53.39
35.69
Tax
101.02
74.36
77.37
62.19
54.38
50.32
43.74
25.44
14.28
12.26
9.76
Tax Rate
18.63%
16.48%
20.05%
19.83%
20.18%
22.18%
23.22%
21.03%
23.78%
22.96%
27.35%
PAT
441.14
376.26
299.84
242.27
215.00
176.56
144.78
95.61
45.77
41.04
25.85
PAT before Minority Interest
437.32
376.99
308.45
251.43
215.08
176.56
144.63
95.50
45.77
41.13
25.93
Minority Interest
-3.82
-0.73
-8.61
-9.16
-0.08
0.00
0.15
0.11
0.00
-0.09
-0.08
PAT Margin
27.06%
25.65%
23.62%
22.83%
24.91%
27.22%
26.82%
23.80%
19.17%
16.30%
14.93%
PAT Growth
23.72%
25.49%
23.76%
12.68%
21.77%
21.95%
51.43%
108.89%
11.53%
58.76%
 
EPS
58.12
49.57
39.50
31.92
28.33
23.26
19.08
12.60
6.03
5.41
3.41

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Shareholder's Funds
1,880.48
1,483.93
1,185.83
947.91
632.91
363.83
224.76
128.14
93.19
61.74
Share Capital
89.76
89.74
89.71
89.71
51.05
15.12
15.12
15.11
15.11
15.11
Total Reserves
1,775.35
1,378.74
1,081.33
848.76
575.01
345.42
209.56
111.40
78.08
46.63
Non-Current Liabilities
2.30
12.55
17.39
24.86
23.42
27.86
19.90
13.69
10.39
10.42
Secured Loans
0.00
0.00
0.00
0.02
0.29
0.32
0.48
0.73
0.88
2.07
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
7.78
8.48
5.69
5.23
0.13
0.00
0.40
1.63
0.82
0.81
Current Liabilities
268.00
207.68
142.85
144.32
86.11
108.67
113.36
125.04
124.97
107.58
Trade Payables
164.37
155.94
88.50
64.14
60.47
94.23
78.60
55.71
41.56
31.50
Other Current Liabilities
99.94
48.68
51.87
79.28
24.20
13.86
33.09
60.39
72.11
66.42
Short Term Borrowings
3.41
0.50
0.00
0.00
0.00
0.00
0.00
0.00
0.05
0.05
Short Term Provisions
0.28
2.56
2.48
0.91
1.44
0.58
1.67
8.94
11.25
9.60
Total Liabilities
2,177.57
1,730.11
1,363.61
1,125.75
742.52
500.45
358.38
267.14
228.82
179.92
Net Block
279.81
286.57
305.34
272.50
226.84
169.48
151.83
144.23
113.13
102.24
Gross Block
480.32
445.74
422.58
354.79
271.51
231.79
195.15
180.76
142.71
123.06
Accumulated Depreciation
200.51
159.17
117.24
82.29
44.67
62.31
43.31
36.53
29.58
20.82
Non Current Assets
623.11
432.29
349.04
303.23
248.83
196.34
179.16
148.61
146.95
131.30
Capital Work in Progress
220.71
17.73
13.88
20.12
9.70
15.29
3.42
0.23
30.63
24.54
Non Current Investment
70.52
37.01
0.66
0.56
0.33
0.33
13.24
0.44
0.45
0.44
Long Term Loans & Adv.
51.68
89.90
7.92
10.05
11.95
11.23
10.67
3.71
2.75
3.67
Other Non Current Assets
0.39
1.08
21.24
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,554.46
1,297.82
1,014.57
822.53
493.69
304.11
179.22
118.53
81.87
48.61
Current Investments
159.17
51.97
10.54
60.23
69.62
46.34
4.20
0.00
0.00
0.00
Inventories
288.22
227.31
179.01
238.23
37.45
28.46
22.29
18.81
13.66
9.79
Sundry Debtors
394.06
317.05
279.36
228.96
159.81
125.88
33.02
7.95
5.66
0.09
Cash & Bank
493.48
462.99
438.33
223.43
152.99
79.28
93.07
68.10
45.37
26.82
Other Current Assets
219.53
13.61
20.25
14.87
73.83
24.16
26.63
23.67
17.18
11.90
Short Term Loans & Adv.
196.81
224.89
87.08
56.81
64.61
17.28
19.31
12.58
11.08
8.16
Net Current Assets
1,286.46
1,090.14
871.72
678.21
407.58
195.44
65.86
-6.51
-43.10
-58.97
Total Assets
2,177.57
1,730.11
1,363.61
1,125.76
742.52
500.45
358.38
267.14
228.82
179.91

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Cash From Operating Activity
271.37
336.73
268.61
44.68
83.42
66.49
67.61
42.40
49.88
59.83
PBT
451.35
385.82
313.62
269.46
226.88
188.38
120.95
60.05
53.39
35.69
Adjustment
11.77
30.44
23.09
7.09
19.12
14.84
8.61
3.87
6.21
2.14
Changes in Working Capital
-103.75
1.96
-1.96
-177.11
-120.06
-100.38
-38.39
-5.13
1.96
29.32
Cash after chg. in Working capital
359.37
418.22
334.75
99.44
125.94
102.84
91.16
58.78
61.56
67.15
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-88.00
-81.49
-66.14
-54.76
-42.51
-36.35
-23.55
-16.38
-11.67
-7.32
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-217.58
-376.77
-29.44
-54.50
-100.46
-69.02
-36.11
-5.72
-22.66
-43.89
Net Fixed Assets
-56.57
-3.66
-35.46
-43.65
58.45
-48.43
-19.56
-7.66
-25.72
-48.50
Net Investments
-169.44
-115.52
46.59
-27.53
-120.03
-29.43
-17.35
0.01
-0.90
0.75
Others
8.43
-257.59
-40.57
16.68
-38.88
8.84
0.80
1.93
3.96
3.86
Cash from Financing Activity
-28.17
-40.68
-23.98
79.77
89.79
-11.60
-6.74
-13.95
-8.67
-5.96
Net Cash Inflow / Outflow
25.62
-80.72
215.19
69.94
72.76
-14.13
24.76
22.73
18.55
9.99
Opening Cash & Equivalents
150.76
231.57
220.77
150.65
77.17
91.31
66.55
45.37
26.82
16.84
Closing Cash & Equivalent
177.56
150.76
435.72
220.77
150.65
77.17
91.31
68.10
45.37
26.82

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Book Value (Rs.)
235.91
183.89
144.94
114.21
78.03
47.69
29.73
16.25
11.84
7.68
ROA
19.29%
19.94%
20.20%
23.02%
28.41%
33.68%
30.54%
18.46%
20.12%
16.48%
ROE
23.68%
24.77%
25.65%
29.58%
37.14%
49.43%
54.97%
43.13%
55.78%
53.24%
ROCE
26.85%
28.77%
28.82%
33.35%
45.59%
64.08%
69.03%
55.41%
71.11%
68.99%
Fixed Asset Turnover
3.17
2.92
2.73
2.76
2.58
2.53
2.14
1.48
1.89
2.00
Receivable days
88.48
85.74
87.41
82.19
80.37
53.72
18.62
10.40
4.17
1.00
Inventory Days
64.15
58.42
71.75
58.28
18.54
17.16
18.68
24.83
17.00
21.31
Payable days
88.14
80.02
59.05
28.33
65.76
89.68
88.17
103.48
69.75
79.69
Cash Conversion Cycle
64.48
64.14
100.11
112.15
33.15
-18.80
-50.88
-68.24
-48.58
-57.39
Total Debt/Equity
0.00
0.00
0.01
0.04
0.00
0.00
0.00
0.02
0.02
0.06
Interest Cover
579.65
552.17
198.25
843.86
391.22
309.72
235.08
179.35
56.11
53.29

News Update:


  • Caplin Point Laboratories’ arm gets final approval from USFDA for Ofloxacin Ophthalmic Solution
    16th Apr 2024, 12:30 PM

    Ofloxacin Ophthalmic Solution USP 0.3% had US sales of around $52 million for the 12- month period ending December 2023

    Read More
  • Caplin Point Laboratories’ arm gets USFDA approval for Ketorolac tromethamine Ophthalmic Solution
    28th Mar 2024, 11:12 AM

    Ketorolac tromethamine Ophthalmic Solution 0.5% had US sales of around $36 million for the 12-month period ending December 2023

    Read More
  • Caplin Point Laboratories’ arm completes new Oncology facility in Kakkalur
    27th Mar 2024, 11:30 AM

    The facility will manufacture tablets, capsules, and injections, catering to the growing demand for high-quality pharmaceuticals in the oncology segment

    Read More
  • Caplin Point Lab - Quarterly Results
    9th Feb 2024, 12:46 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.